Disinhibition of CA1 pyramidal cells by low-dose ketamine and other antagonists with rapid antidepressant efficacy
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
Significance: Ketamine is an NMDA receptor (NMDAR) antagonist that alleviates depressive symptoms in patients with treatment-resistant depression within hours of administering a single dose. However, psychoactive side effects limit its use. Understanding the mechanism underlying ketamine’s antidepressant effect is crucial in identifying targets for novel therapeutics with fewer side effects. Here, we report ketamine enhances excitability of pyramidal cells indirectly by reducing synaptic GABAergic inhibition, thus causing disinhibition. Additionally, we investigated whether other NMDAR antagonists and the muscarinic acetylcholine receptor antagonist scopolamine shared this disinhibition mechanism. Our results show that only those antagonists with antidepressant efficacy in humans disinhibit pyramidal cells at a clinically relevant concentration, supporting the concept that disinhibition is likely involved in the antidepressant effect of these antagonists.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Intriguingly, the lack of an effect on action potential probability may be due to differential effects of Ro-256981 on individual cells, given that only a subset of cells showed an increase or showed a decrease following treatment.”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Widman & McMahon, 2018
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“At subanesthetic doses, ketamine preferentially antagonizes N-methyl-D-aspartate receptors (NMDARs) on fast spiking GABAergic interneurons, releasing pyramidal neurons from inhibitory control [42,43,44,45,46].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [43]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“First, a study using rat hippocampal slices observed that ketamine (1 μM, 20-minute bath application) enhanced the action potential probability in CA1 measured through a disinhibition of pyramidal neurons”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Widman & McMahon, 2018
The cited source says what the claim attributes to it.
In the citing paper
“Conversely, Ro25-6981 (1 μM, 20-minute bath application) does not significantly impact action potential probability and increases inhibitory currents.”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Widman & McMahon, 2018
In the citing paper
“These oscillations are likely to result from disinhibition produced by a selective block of NMDARs on GABAergic interneurons [142, 143].”
From Plasticity of synapses and reward circuit function in the genesis and treatment of depression (2023) · cites this paper as [143]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · cited 1×
“At higher concentrations, ketamine decreases excitatory transmission (40) and has no antidepressantlike effects in rodent models (7), so the concentration used is critical.”
BackgroundNMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926 · cited 3×
“This chain of events would lead to the desuppression of eEF2 kinase and increased protein translation (15, 16).”
BackgroundMoghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793 · cited 1×
“ketamine administration concurrent with elevated extracellular glutamate (10, 11).”
BackgroundSynaptic plasticity and depression: new insights from stress and rapid-acting antidepressants
Duman, R. S., Aghajanian, G. K., Sanacora, G., & Krystal, J. H. (2016) · Nature Medicine · doi:10.1038/nm.4050 · Cited by 1,750
Synaptic Dysfunction in Depression: Potential Therapeutic Targets
Duman, R. S., & Aghajanian, G. K. (2012) · Science · doi:10.1126/science.1222939 · Cited by 1,651
NMDAR inhibition-independent antidepressant actions of ketamine metabolites
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609
Reduction of Prefrontal Cortex Glucose Metabolism Common to Three Types of Depression
Baxter, L. R. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810030049007 · Cited by 1,320
Homayoun, H., & Moghaddam, B. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2213-07.2007 · Cited by 1,231
Maeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103
Li, N., Liu, R.-J., Dwyer, J. M., Banasr, M., Lee, B., Son, H., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.12.015 · Cited by 1,082
Course of illness, hippocampal function, and hippocampal volume in major depression
MacQueen, G. M., Campbell, S., McEwen, B. S., Macdonald, K., Amano, S., Joffe, R. T., Nahmias, C., & Young, L. T. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0337481100 · Cited by 980 · cited 3×
“These data suggest that pyramidal cell disinhibition downstream of NMDAR antagonism could serve as a possible biomarker for the efficacy of rapid antidepressant therapy. excitation/inhibition balance | major depression | disinhibition | GABAergic transmission | hippocampal networks Ketamine, an open-channel N-methyl D…”
BackgroundHippocampal sharp waves: Their origin and significance
Buzsáki, G. (1986) · Brain Research · doi:10.1016/0006-8993(86)91483-6 · Cited by 925
Magarin˜os, A. M., & McEwen, B. S. (1995) · Neuroscience · doi:10.1016/0306-4522(95)00259-l · Cited by 863
Sousa, N., Lukoyanov, N. V., Madeira, M. D., Almeida, O. F. X., & Paula-Barbosa, M. M. (2000) · Neuroscience · doi:10.1016/s0306-4522(00)00050-6 · Cited by 758
Ketamine Pharmacology: An Update ( Pharmacodynamics and Molecular Aspects, Recent Findings )
Mion, G., & Villevieille, T. (2013) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12099 · Cited by 711 · cited 1×
“Additionally, memantine has a longer half-life (42, 44) than ketamine, potentially leading to prolonged NMDAR antagonism and circuit effects, possibly explaining its lack of antidepressant efficacy in rodent models (43) and patients (45, 46).”
BackgroundParsons, C. G., Stöffler, A., & Danysz, W. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.07.013 · Cited by 707
Roberson, E. D., Halabisky, B., Yoo, J. W., Yao, J., Chin, J., Yan, F., Wu, T., Hamto, P., Devidze, N., Yu, G.-Q., et al. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.4152-10.2011 · Cited by 654 · cited 1×
“the length of thewaveform,was used to analyze changes in excitability (60, 61).”
MethodKamondi, A., Acsády, L., Wang, X.-J., & Buzsáki, G. (1998) · Hippocampus · doi:10.1002/(sici)1098-1063(1998)8:3<244::aid-hipo7>3.0.co;2-j · Cited by 531
Preskorn, S. H., Baker, B., Kolluri, S., Menniti, F. S., Krams, M., & Landen, J. W. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31818a6cea · Cited by 518
Garcia, L. S. B., Comim, C. M., Valvassori, S. S., Réus, G. Z., Barbosa, L. M., Andreazza, A. C., Stertz, L., Fries, G. R., Gavioli, E. C., Kapczinski, F., et al. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.07.027 · Cited by 454
Furey, M. L., & Drevets, W. C. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.10.1121 · Cited by 417
A Double-Blind, Placebo-Controlled Study of Memantine in the Treatment of Major Depression
Zarate, C. A., Singh, J. B., Quiroz, J. A., De Jesus, G., Denicoff, K. K., Luckenbaugh, D. A., Manji, H. K., & Charney, D. S. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.153 · Cited by 387
BDNF release is required for the behavioral actions of ketamine
Lepack, A. E., Fuchikami, M., Dwyer, J. M., Banasr, M., & Duman, R. S. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu033 · Cited by 368
Miller, O. H., Yang, L., Wang, C.-C., Hargroder, E. A., Zhang, Y., Delpire, E., & Hall, B. J. (2014) · eLife · doi:10.7554/elife.03581 · Cited by 358
Burgdorf, J., Zhang, X.-L., Nicholson, K. L., Balster, R. L., David Leander, J., Stanton, P. K., Gross, A. L., Kroes, R. A., & Moskal, J. R. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.246 · Cited by 284
Acute suppression of spontaneous neurotransmission drives synaptic potentiation
Nosyreva, E., Szabla, K., Autry, A. E., Ryazanov, A. G., Monteggia, L. M., & Kavalali, E. T. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.4998-12.2013 · Cited by 283 · cited 1×
“, 20 μM) (16, 18, 39) than what is believed to occur in human brain (30), and electrophysiological measurements were made at time frames too late to capture the most immediate effects on neuronal excitability and synaptic circuits.”
BackgroundWagner, G., Sinsel, E., Sobanski, T., Köhler, S., Marinou, V., Mentzel, H.-J., Sauer, H., & Schlösser, R. G. M. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.10.025 · Cited by 278
Korn, S. J., Giacchino, J. L., Chamberlin, N. L., & Dingledine, R. (1987) · Journal of Neurophysiology · doi:10.1152/jn.1987.57.1.325 · Cited by 266
Voleti, B., Navarria, A., Liu, R.-J., Banasr, M., Li, N., Terwilliger, R., Sanacora, G., Eid, T., Aghajanian, G., & Duman, R. S. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.04.025 · Cited by 264
Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity
Gerhard, D. M., Wohleb, E. S., & Duman, R. S. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.01.016 · Cited by 261
Duman, R. S. (2014) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2014.16.1/rduman · Cited by 249
Drevets, W. C., & Furey, M. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.11.021 · Cited by 241
The regulation of quantal size
Van der Kloot, W. (1991) · Progress in Neurobiology · doi:10.1016/0301-0082(91)90019-w · Cited by 239
Gideons, E. S., Kavalali, E. T., & Monteggia, L. M. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1323920111 · Cited by 232 · cited 3×
“While there are conflicting reports on HNK’s ability to block NMDARs, it seems to enhance glutamatergic transmission mediated by AMPARs, which is required for the antidepressant-like effects in mice (19, 20, 43).”
BackgroundIbrahim, L., DiazGranados, N., Jolkovsky, L., Brutsche, N., Luckenbaugh, D. A., Herring, W. J., Potter, W. Z., & Zarate, C. A. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31825d70d6 · Cited by 220 · cited 1×
“While some clinical trials have demonstrated antidepressant efficacy of GluN2B subunit-selective NMDAR antagonists, others report no significant improvement in depressive symptoms (33, 34).”
BackgroundMiller, O. H., Moran, J. T., & Hall, B. J. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.07.028 · Cited by 200
The role of eukaryotic elongation factor 2 kinase in rapid antidepressant action of ketamine
Monteggia, L. M., Gideons, E., & Kavalali, E. T. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.09.006 · Cited by 198
PRESKORN, S., MACALUSO, M., MEHRA, D. V., ZAMMIT, G., MOSKAL, J. R., & BURCH, R. M. (2015) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000462606.17725.93 · Cited by 193
Smith, C. C., & McMahon, L. L. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.5279-05.2006 · Cited by 189
Self-citationEffects of a ketamine metabolite on synaptic NMDAR function
Suzuki, K., Nosyreva, E., Hunt, K. W., Kavalali, E. T., & Monteggia, L. M. (2017) · Nature · doi:10.1038/nature22084 · Cited by 180
GABA interneurons mediate the rapid antidepressant-like effects of scopolamine
Wohleb, E. S., Wu, M., Gerhard, D. M., Taylor, S. R., Picciotto, M. R., Alreja, M., & Duman, R. S. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85033 · Cited by 144
Inhibitory control of hippocampal inhibitory neurons
Chamberland, S., & Topolnik, L. (2012) · Frontiers in Neuroscience · doi:10.3389/fnins.2012.00165 · Cited by 134 · cited 1×
“glutamatergic synapses in hippocampus and cortex (54), and certain subclasses provide synaptic inhibition onto other interneurons (55).”
BackgroundFischell, J., Van Dyke, A. M., Kvarta, M. D., LeGates, T. A., & Thompson, S. M. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.112 · Cited by 122 · cited 1×
“Additionally, a new negative allosteric modulator of GABAARs, which reduces inhibition and shifts the I/E balance toward excitation, has a rapid antidepressant-like effect in rodent models (56, 57).”
BackgroundHartvig, P., Valtysson, J., Lindner, K., Kristensen, J. D., Karlsten, R., Gustafsson, L. L., Persson, J., Svensson, J. O., Øye, I., Antoni, G., et al. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90194-9 · Cited by 120
Navarria, A., Wohleb, E. S., Voleti, B., Ota, K. T., Dutheil, S., Lepack, A. E., Dwyer, J. M., Fuchikami, M., Becker, A., Drago, F., et al. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.06.012 · Cited by 118
Zhang, X.-L., Sullivan, J. A., Moskal, J. R., & Stanton, P. K. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.08.018 · Cited by 114
Witkin, J. M., Overshiner, C. D., Li, X., Catlow, J. T., Wishart, G. N., Schober, D. A., Heinz, B. A., Nikolayev, A., Tolstikov, V., Anderson, W. H., et al. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.216804 · Cited by 110
Developmental origin dictates interneuron AMPA and NMDA receptor subunit composition and plasticity
Matta, J. A., Pelkey, K. A., Craig, M. T., Chittajallu, R., Jeffries, B. W., & McBain, C. J. (2013) · Nature Neuroscience · doi:10.1038/nn.3459 · Cited by 108 · cited 1×
“glutamatergic synapses in hippocampus and cortex (54), and certain subclasses provide synaptic inhibition onto other interneurons (55).”
Zanos, P., Nelson, M. E., Highland, J. N., Krimmel, S. R., Georgiou, P., Gould, T. D., & Thompson, S. M. (2017) · eNeuro · doi:10.1523/eneuro.0285-16.2017 · Cited by 106
Therapeutic Modulation of Glutamate Receptors in Major Depressive Disorder
Jaso, B. A., Niciu, M. J., Iadarola, N. D., Lally, N., Richards, E. M., Park, M., Ballard, E. D., Nugent, A. C., Machado-Vieira, R., & Zarate, C. A. (2017) · Current Neuropharmacology · doi:10.2174/1570159x14666160321123221 · Cited by 98
Zhang, K., Xu, T., Yuan, Z., Wei, Z., Yamaki, V. N., Huang, M., Huganir, R. L., & Cai, X. (2016) · Science Signaling · doi:10.1126/scisignal.aai7884 · Cited by 98 · cited 1×
“, 20 μM) (16, 18, 39) than what is believed to occur in human brain (30), and electrophysiological measurements were made at time frames too late to capture the most immediate effects on neuronal excitability and synaptic circuits.”
BackgroundSmith, E. G., Deligiannidis, K. M., Ulbricht, C. M., Landolin, C. S., Patel, J. K., & Rothschild, A. J. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12m08252 · Cited by 82 · cited 1×
“Additionally, memantine has a longer half-life (42, 44) than ketamine, potentially leading to prolonged NMDAR antagonism and circuit effects, possibly explaining its lack of antidepressant efficacy in rodent models (43) and patients (45, 46).”
BackgroundVedder, L. C., Smith, C. C., Flannigan, A. E., & McMahon, L. L. (2013) · Hippocampus · doi:10.1002/hipo.22068 · Cited by 79
Self-citationPozzi, L., Dorocic, I. P., Wang, X., Carlén, M., & Meletis, K. (2014) · PLoS ONE · doi:10.1371/journal.pone.0083879 · Cited by 74
Metaplastic Effects of Subanesthetic Ketamine on CA1 Hippocampal Function
Izumi, Y., & Zorumski, C. F. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.08.002 · Cited by 63
Effects of memantine on the excitation-inhibition balance in prefrontal cortex
Povysheva, N. V., & Johnson, J. W. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.08.006 · Cited by 56
Kim, C. S., Brager, D. H., & Johnston, D. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.28 · Cited by 55
Bredemann, T. M., & McMahon, L. L. (2014) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2014.01.004 · Cited by 51
Self-citationMartin, A. E., Schober, D. A., Nikolayev, A., Tolstikov, V. V., Anderson, W. H., Higgs, R. E., Kuo, M.-S., Laksmanan, A., Catlow, J. T., Li, X., et al. (2017) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527316666170309142646 · Cited by 35
Sanacora, G. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.0780 · Cited by 12
Cited by
Duman, R. S., Sanacora, G., & Krystal, J. H. (2019) · Neuron · doi:10.1016/j.neuron.2019.03.013 · Cited by 1,026
Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels
Hansen, K. B., Wollmuth, L. P., Bowie, D., Furukawa, H., Menniti, F. S., Sobolevsky, A. I., Swanson, G. T., Swanger, S. A., Greger, I. H., Nakagawa, T., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000131 · Cited by 686
Brain-Derived Neurotrophic Factor Signaling in Depression and Antidepressant Action
Castrén, E., & Monteggia, L. M. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.05.008 · Cited by 540
GABA interneurons are the cellular trigger for ketamine's rapid antidepressant actions
Gerhard, D. M., Pothula, S., Liu, R.-J., Wu, M., Li, X.-Y., Girgenti, M. J., Taylor, S. R., Duman, C. H., Delpire, E., Picciotto, M., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci130808 · Cited by 345
Ketamine: A tale of two enantiomers
Jelen, L. A., Young, A. H., & Stone, J. M. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120959644 · Cited by 246
Metadata
- Authors
- Widman, A. J., & McMahon, L. L.
- Affiliations
- University of Alabama at Birmingham (US)
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2018-03-12
- Volume
- 115
- Issue
- 13
- Pages
- E3007-E3016
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC5879689
- OpenAlex
- W2794102241
- Cited by
- 204
- References
- 64
- Citations by year
- 2026: 11 · 2025: 19 · 2024: 17 · 2023: 27 · 2022: 30 · 2021: 32 · 2020: 37 · 2019: 20 · 2018: 9
- FWCI
- 15.81
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- HHS | NIH | National Institute of Mental Health (1F31MH110096, R56 MH107190)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- ketamine, rapid antidepressant effects, disinhibition, CA1 pyramidal neurons, NMDA receptor antagonism, Ro 25-6981, scopolamine, muscarinic receptors, GABAergic interneurons, synaptic inhibition, excitation-inhibition balance, dorsal hippocampus
- MeSH terms
- Action Potentials, Animals, Antidepressive Agents, Depressive Disorder, Hippocampus, Interneurons, Ketamine, Male, Neuronal Plasticity, Scopolamine, Synapses, Receptors, N-Methyl-D-Aspartate, Rats, Sprague-Dawley, Pyramidal Cells, Excitatory Amino Acid Antagonists, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.